IRVINE, Calif., March 27 /PRNewswire-FirstCall/ -- Dermisonics, Inc. , a pioneer in the development of painless injection-free ultrasonic transdermal drug-delivery technologies with broad pharmaceutical and consumer applications, announced today that it had appointed Grant Atkins to its Board of Directors.
Mr. Atkins, currently President and Director Lexington Resources, Inc., an oil and gas exploration and development company, has a fifteen-year entrepreneurial record of success with extensive multi-industry credentials in the fields of finance, administration and business development. His previous industry experience includes:
-- Biotech cancer immunotherapy (GeneMax Corp.), President -- Mining and exploration in China (Vega-Atlantic Corporation), President -- Electronic Data Processing (Transax International Limited), President, and -- A $200 million (CDN funds) radio and tri-service dispatch initiative and deployment of Canadian federal, provincial and municipal shareholders as interim Chief Financial Officer of Emergency Communications for Southwest British Columbia (“E-Comm”).
Mr. Atkins has extensive public company governance and operational experience handling all aspects relating to public company finance and administration including SEC filings, registration statements, financial statement preparation, audit liaison, audit and ethics committee operation, proxy statement and annual meeting, business planning, cash flow controls, Sarbanes Oxley compliance, trading dynamics, and investor relations. He is a Graduate of University of British Columbia with a Bachelors of Commerce Degree.
Bruce Haglund, CEO of Dermisonics, commented, “Grant’s extensive financial and operations experience at the most senior management levels coupled with his entrepreneurial mindset will be a major asset in our drive to exploit the rich applications potential of Dermisonic’s technology in the drug, cosmetic and antiseptic industries.”
About Dermisonics, Inc. -- Dermisonics is an intellectual property company and advanced technology incubator that is primarily focused on developing and marketing its transdermal and subdermal technologies for applications in the drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields. Its breakthrough system, called the U-Strip, facilitates the efficient and needle-free delivery of drugs with large molecular structures into the bloodstream. This system is based on a radical integration of microelectronics and ultrasonic science with a product-carrying patch and represents a quantum leap in non-invasive, transdermal delivery technology. Tests have shown that the U-Strip facilitates the transdermal delivery of Insulin as well as potentially at least 175 other existing drugs through the pores of the skin. Conventionally available transdermal technology cannot effectively deliver these drugs due to their large molecular size. The Company has also developed major line extensions for applications in the medical (Antiseptic Wand) and skin care (U-Wand) fields.
For further information contact Bruce Haglund, CEO. bruce.haglund@dermisonics.com Dermisonics, Inc. Jamboree Center 2 Park Plaza, Suite 450 Irvine, California 92614 888-401-DERM (3376) Toll Free 949-733-1101 Phone 949-266-8426 Fax Web site: www.Dermisonics.com North American Investor Relations Contact: Brent Pierce, International Marketing Trend, Inc. Phone: 877-676-4447 brent@brentpierce.com European Investor Relations Contact: Michael Drepper Phone: +49-621-430-6130 investor-germany@dermisonics.com Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward- looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company’s products, technical problems with the Company’s research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company’s operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company’s ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.
Dermisonics, Inc.
CONTACT: Bruce Haglund, CEO, Toll Free, 1-888-401-DERM (3376), or+1-949-733-1101, or fax, +1-949-266-8426, or bruce.haglund@dermisonics.com,or Europe, Michael Drepper, +49-621-430-6130, orinvestor-germany@dermisonics.com, both of Dermisonics, Inc.; or BrentPierce of International Marketing Trend, Inc., 1-877-676-4447, orbrent@brentpierce.com, for Dermisonics, Inc.
Web site: http://www.dermisonics.com/
